WEKO3
アイテム
Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody.
https://repo.qst.go.jp/records/49467
https://repo.qst.go.jp/records/49467dfe30128-913b-40ec-8a54-c7dacf3c7b1a
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-01-16 | |||||
タイトル | ||||||
タイトル | Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody. | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
U, Winn Aung
× U, Winn Aung× Tsuji, Atsushi× Sudo, Hitomi× Sugyo, Aya× Ukai, Yoshinori× Kouda, Katsushi× Kurosawa, Yoshikazu× Furukawa, Takako× Saga, Tsuneo× U Winn Aung× 辻 厚至× 須藤 仁美× 須尭 綾× 古川 高子× 佐賀 恒夫 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The contribution of integrin α6β4 (α6β4) overexpression to the pancreatic cancer invasion and metastasis has been previously shown. We have reported immunotargeting of α6β4 for radionuclide-based and near-infrared fluorescence imaging in a pancreatic cancer model. In this study, we prepared yttrium-90 labeled anti-α6β4 antibody (90Y-ITGA6B4) and evaluated its radioimmunotherapeutic efficacy against pancreatic cancer xenografts in nude mice. Mice bearing xenograft tumors were randomly divided into 5 groups: (1) single administration of 90Y-ITGA6B4 (3.7MBq), (2) double administrations of 90Y-ITGA6B4 with once-weekly schedule (3.7MBq x 2), (3) single administration of unlabeled ITGA6B4, (4) double administrations of unlabeled ITGA6B4 with once-weekly schedule and (5) the untreated control. Biweekly tumor volume measurements and immunohistochemical analyses of tumors at 2 days post-administration were performed to monitor the response to treatments. To assess the toxicity, body weight was measured biweekly. Additionally, at 27 days post-administration, blood samples were collected through cardiac puncture, and hematological parameters, hepatic and renal functions were analyzed. Both 90Y-ITGA6B4 treatment groups showed reduction in tumor volumes (P < 0.04), decreased cell proliferation marker Ki-67-positive cells and increased DNA damage marker p-H2AX-positive cells, compared with the other groups. Mice treated with double administrations of 90Y-ITGA6B4, exhibited myelosuppression. There were no significant differences in hepatic and renal functions between the 2 treatment groups and the other groups. Our results suggest that 90Y-ITGA6B4 is a promising radioimmunotherapeutic agent against α6β4 overexpressing tumors. In the future studies, dose adjustment for fractionated RIT should be considered carefully in order to get the optimal effect while avoiding myelotoxicity. |
|||||
書誌情報 |
Oncotarget 巻 7, 号 25, p. 38835-38844, 発行日 2016-06 |
|||||
出版者 | ||||||
出版者 | Inpact Journals | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1949-2553 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 27246980 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.18632/oncotarget.9631 | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | www.impactjournals.com/oncotarget/ | |||||
関連名称 | www.impactjournals.com/oncotarget/ |